of cholesterol esters and then get incorporated into macrophages. LPL creates free fatty acids, and macrophages then re-esterify them, accumulating cholesterol esters in macrophages, causing macrophages to transform into foam cells. LPL catalyzed the conversion of VLDL to Intermediate density lipoproteins (IDL), which hepatic lipases then convert to low-density lipoprotein (LDL). Foam cells also form when macrophages incorporate oxidized LDL via their scavenger receptor in the vascular endothelium.[10] ## Review Questions - [Access free multiple choice questions on this topic.](https://www.statpearls.com/account/trialuserreg/?articleid=24324&utm_source=pubmed&utm_campaign=reviews&utm_content=24324) - [Comment on this article.](https://www.statpearls.com/articlelibrary/commentarticle/24324/?utm_source=pubmed&utm_campaign=comments&utm_content=24324) ## References 1. Mead JR, Irvine SA, Ramji DP. Lipoprotein lipase: structure, function, regulation, and role in disease. J Mol Med (Berl). 2002 Dec;80(12):753-69. \[[PubMed: 12483461](https://pubmed.ncbi.nlm.nih.gov/12483461)\] 2. Beigneux AP, Allan CM, Sandoval NP, Cho GW, Heizer PJ, Jung RS, Stanhope KL, Havel PJ, Birrane G, Meiyappan M, Gill JE, Murakami M, Miyashita K, Nakajima K, Ploug M, Fong LG, Young SG. Lipoprotein lipase is active as a monomer. Proc Natl Acad Sci U S A. 2019 Mar 26;116(13):6319-6328. \[[PMC free article: PMC6442593](/pmc/articles/PMC6442593/)\] \[[PubMed: 30850549](https://pubmed.ncbi.nlm.nih.gov/30850549)\] 3. Arora R, Nimonkar AV, Baird D, Wang C, Chiu CH, Horton PA, Hanrahan S, Cubbon R, Weldon S, Tschantz WR, Mueller S, Brunner R, Lehr P, Meier P, Ottl J, Voznesensky A, Pandey P, Smith TM, Stojanovic A, Flyer A, Benson TE, Romanowski MJ, Trauger JW. Structure of lipoprotein lipase in complex with GPIHBP1. Proc Natl Acad Sci U S A. 2019 May 21;116(21):10360-10365. \[[PMC free article: PMC6534989](/pmc/articles/PMC6534989/)\] \[[PubMed: 31072929](https://pubmed.ncbi.nlm.nih.gov/31072929)\] 4. Gunn KH, Roberts BS, Wang F, Strauss JD, Borgnia MJ, Egelman EH, Neher SB. The structure of helical lipoprotein lipase reveals an unexpected twist in lipase storage. Proc Natl Acad Sci U S A. 2020 May 12;117(19):10254-10264. \[[PMC free article: PMC7229681](/pmc/articles/PMC7229681/)\] \[[PubMed: 32332168](https://pubmed.ncbi.nlm.nih.gov/32332168)\] 5. Falko JM. Familial Chylomicronemia Syndrome: A Clinical Guide For Endocrinologists. Endocr Pract. 2018 Aug;24(8):756-763. \[[PubMed: 30183397](https://pubmed.ncbi.nlm.nih.gov/30183397)\] 6. Blom DJ, O'Dea L, Digenio A, Alexander VJ, Karwatowska-Prokopczuk E, Williams KR, Hemphill L, Mu√±iz-Grijalvo O, Santos RD, Baum S, Witztum JL. Characterizing familial chylomicronemia syndrome: Baseline data of the APPROACH study. J Clin Lipidol. 2018 Sep-Oct;12(5):1234-1243.e5. \[[PubMed: 30318066](https://pubmed.ncbi.nlm.nih.gov/30318066)\] 7. Yuan G, Al-Shali KZ, Hegele RA. Hypertriglyceridemia: its etiology, effects and treatment. CMAJ. 2007 Apr 10;176(8):1113-20. \[[PMC free article: PMC1839776](/pmc/articles/PMC1839776/)\] \[[PubMed: 17420495](https://pubmed.ncbi.nlm.nih.gov/17420495)\] 8. Blackett P, Tryggestad J, Krishnan S, Li S, Xu W, Alaupovic P, Quiroga C, Copeland K. Lipoprotein abnormalities in compound heterozygous lipoprotein lipase deficiency after treatment with a low-fat diet and orlistat. J Clin Lipidol.